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Abstract 
Background: Emerging evidence suggests poor antiretroviral penetration within human 
gastrointestinal (GI) tissues may contribute to HIV persistence within reservoirs despite effective 
therapy. We hypothesize that HIV infection induces an upregulation of drug efflux pumps P-
glycoprotein and Breast Cancer Resistance Protein (BCRP) within GI lymphocytes which may 
limit antiretroviral accumulation within these cells. The mechanism of upregulation may be 
related to the HIV-1 protein Tat, which generates oxidative stress.  
Methods: Primary lymphocytes were isolated from human blood and co-cultured with Caco2 
cells in a Transwell® configuration to model the in vivo environment of the human intestine. 
Cells were infected with HIV and triplicate samples were lysed over a 7 day time course. 
Primary lymphocytes were also treated with 0.1nM Tat for 24 hours. Lymphocyte and Caco2 
samples were immunoblotted for P-glycoprotein and BCRP expression using β-actin to 
normalize. Tat treated samples were additionally probed for peroxiredoxin sulfate, a marker for 
oxidative stress marker, and standardized to 2-cys- peroxiredoxin. 
Results: P-glycoprotein expression was increased in both HIV-infected, activated and resting 
lymphocytes compared to uninfected controls.  BCRP expression was also increased in HIV-
infected resting lymphocytes compared to controls. Additionally, P-glycoprotein expression was 
increased by 43% in lymphocytes treated with Tat (p < 0.05). No difference in BCRP expression 
was observed in Tat exposed lymphocytes (8% increase, p<0.05). Peroxiredoxin sulfate trended 
toward being increased (27%) in Tat treated lymphocytes (p>0.05). Little change was observed 
in the expression of P-glycoprotein and BCRP in Caco2 cells exposed to HIV. 
Conclusions: These data demonstrate an upregulation of two drug efflux proteins important in 
HIV pharmacology, P-glycoprotein and BCRP, in HIV-infected primary lymphocytes grown in 
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an in vitro intestinal model. Furthermore, Tat may contribute to the increased expression of P-
glycoprotein through oxidative stress as indicated by the elevation of peroxiredoxin sulfate in Tat 
treated cells. These results suggest a mechanism to explain decreased antiretroviral 
concentrations within the lymphoid rich regions of the GI tract, an important viral reservoir. 
Understanding the mechanisms of decreased antiretroviral accumulation within reservoir tissues 
will be critical in developing therapies to modulate and optimize HIV treatment.  
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Background 
 Introduction 
Although there have been many advances in treatment, there is currently no cure for 
HIV-1.  Since the beginning of this epidemic 31 years ago, over 60 million people have been 
infected with HIV and 25 million have died from HIV-related causes.1  HIV-infected individuals 
suffer from a high disease burden and are required to remain on combinations of drugs 
throughout their lifetime.  Therapies can result in a decrease in viral load to below the limit of 
detection but if antiretroviral therapy is discontinued, viral replication resumes. This is due in 
part to the presence of viral reservoirs, tissues where the virus is able to persist despite 
“effective” therapy.2  Viral reservoirs include the central nervous system (CNS), male and 
female genital tract, seminal fluids, and the gastrointestinal (GI) tract.  The GI tract is known to 
be an important reservoir because the Gut Associated Lymphoid Tissue (GALT) is 
disproportionately infected with HIV compared to peripheral blood, even in patients receiving 
therapy.3   
One new and emerging theory for the mechanism of reservoir maintenance is that 
antiretroviral drug penetration is decreased in reservoir tissues.  Indeed, variable drug 
concentrations have been seen in the lymphoid tissues of the GI tract. Schacker et al. recently 
reported  data  (from 5 antiretroviral naïve subjects) indicating that despite the fact that initiation 
of highly active antiretroviral therapy (HAART) resulted in a drop in HIV viral concentrations 
(to undetectable limits in blood), virus could still be detected in gut tissues.4 Furthermore, 
Fletcher et al. have reported that concentrations of the antiretroviral drugs within these same gut 
lymph tissues was variable and often did not reach therapeutic concentrations.4  
2 
Given these significant discoveries, it is important to consider potential mechanisms of 
decreased antiretroviral accumulation with HIV reservoir tissues including the gastrointestinal 
tract. Decreased drug concentrations within selected reservoirs could be related to increased 
efflux of antiretroviral drugs. Increased expression of drug efflux pumps such as P-glycoprotein 
and Breast Cancer Resistance Protein (BCRP), which are responsible for the efflux of many 
antiretroviral drugs, by HIV infection could result decreased accumulation of antiretroviral drugs 
within reservoir tissues.  (see Table 1 for a complete list of antiretroviral substrates 5, 6) Both P-
glycoprotein and BCRP are normally expressed in healthy tissues including lymphocytes7, 8.  
Alterations in drug efflux proteins within reservoir cells (ie, lymphocytes of the GI tract) could 
be responsible for restricting antiretroviral accumulation within reservoir tissues because of 
increased drug transport out of cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
Table 1: Antiretroviral drugs known to be substrates of P-glycoprotein and BCRP 
Substrates of  
P-glycoprotein 
Substrates of  
BCRP 
Protease Inhibitors (PIs) 
Saquinavir Atazanavir 
Ritonavir Lopinavir 
Indinavir Nelfinavir 
Nelfinavir   
Amprenavir   
Lopinavir   
Atazanavir   
Tipranavir   
Darunavir   
Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
None Delavirdine 
Nucleoside Reverse Transcripatase Inhibitors (NRTIs) 
Zidovudine* Zidovudine 
Abacavir Stavudine* 
Tenofovir DF Lamivudine 
  Abacavir 
Entry inhibitors 
Raltegravir None 
Elvitegravir   
Maraviroc   
* indicates conflicting evidence in the literature 
Summarized from Weiss (2010)5 and Szakacs (2008) 6  
 
There are several possible mechanisms by which HIV infection could enhance activity 
and/or expression of drug efflux pumps. The HIV-1 protein transactivator of transcription (Tat) 
enhances the efficiency of HIV transcription and replication and is known to increase the 
expression of cytokines and promote infection.9  Within the brain, Tat has been shown to 
increase the expression of P-glycoprotein and another important efflux pump (MRP1) in the 
microvascular endothelium of the blood brain barrier.10 However, to date, Tat effects on drug 
efflux proteins within the GI reservoir  have not been examined.Tat effects, Because Tat is 
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known to disrupt pathways that maintain intracellular oxidative balance, any Tat related effects 
on  drug efflux protein expression could be related to elevated levels of oxidative stress, 11, 12.    
Study Objective 
Despite being capable of suppressing viral concentrations to below detectable limits in 
blood plasma, current antiretroviral therapies cannot completely eradicate HIV from infected 
individuals. This is due, in part, to the presence of viral reservoirs throughout the body.  Given 
the important roles of P-glycoprotein and BCRP in the transport of therapies involved in HIV 
infection, it is likely that an increase in expression of either of these drug efflux proteins in 
lymphoid tissue of the GI tract would result in decreased accumulation of many antiretrovirals 
within this important reservoir site.  Therefore the effect of HIV infection on the expression of 
these proteins is of interest to understanding the maintenance of the viral reservoir in the 
gastrointestinal tract.  
 This study was designed to investigate the mechanisms which dictate diminished 
distribution of antiretroviral drugs into GI lymphoid tissue. Our hypothesis is that HIV infection 
of the lymphoid rich regions of the gastrointestinal tract (ie, the reservoir) causes increases in the 
expression of the drug efflux proteins P-glycoprotein and BCRP, which are responsible for the 
transport of HIV drugs out of target cells.  Changes in the expression of these proteins may result 
in decreased antiretroviral accumulation within the reservoir.  We anticipated increases in drug 
efflux protein expression would only occur in the lymphocytes and not in enterocytes, as 
increased efflux out of enterocytes could impair systemic absorption.  The objective of this study 
was to measure the effects of HIV infection on drug transport protein expression in an in vitro 
co-culture model of the human intestinal tract using isolated primary human lymphocytes and 
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Caco2 cells (enterocyte cell line) and to examine the role of the HIV protein Tat as a potential 
mechanism for observed changes in drug efflux protein expression.  
Materials and Methods 
Chemicals 
Interleukin-2, phytohaemagglutinin (PHA), Tumor Necrosis Factor-Alpha (TNF-α), and 
gluteraldehyde were purchased from Sigma-Aldrich (St. Louis, MO). Ficoll-Paque Plus was 
purchased from GE Healthcare (Pittsburgh, PA). Potassium ferrocyanide and potassium 
ferricyanide were purchased from RICCA (Arlington, TX). Magnesium chloride and Fetal 
Bovine Serum (FBS) were purchased from Thermo Fisher (Waltham, MA). X-gal (5-bromo-4-
chloro-3-indolyl-β-D-galactoside) was purchased from Life Technologies (Carlsbad, CA). 
Formaldehyde was purchased from VWR (Radnor, PA). 
Cell Lines and Virus 
 Cell culture reagents were obtained from Life Technologies (Carlsbad, CA) unless 
otherwise indicated. The following agent was obtained through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: J1 from Dr. Thomas Folks. J1.1 
cells are a Jurkat derived cell line that produces HIV (CXCR4 tropic LAI strain) upon induction 
with TNF-α (10ng/mL). Jurkat E6-1 cells, a human leukemic T cell lymphoblast line, were 
purchased from American Type Culture Collection (ATCC) #TIB-152 (Manassas, VA), infected 
with HIV and used to propogate the CXCR4-tropic LAI strain of HIV.  MDCK-MDR1 cells 
were a generous gift from Dr. Jeff Krise (University of Kansas School of Pharmacy, Lawrence, 
KS).  This cell line originates from Madin Darby canine kidney cells, that overexpress P-
glycoprotein due to a stable transfection with MDR1, and was used as a positive control for P-
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glycoprotein. Caco-2 cells, derived from human colonic adenocarcinoma cells, were purchased 
from ATCC #HTB-37 and were used as an enterocyte model. Caco2 cells, a human colon cancer 
derived cell line, when cultured in a Transwell format for 21-24 days become polarized and 
develop appropriate localization of drug transport proteins and therefore serve as a model for 
intestinal enterocytes.13 Caco-2 cells passaged at least 50 times were used as positive control for 
BCRP, as high passage Caco-2 cells have been shown to express a 3-fold increase in BCRP 
compared to lower passage Caco-2 cells.14 The following reagent was obtained through the NIH 
AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl from 
Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. TZM-bl cells were used for virus 
quantification as they are indicator cells for a β-galactosidase assay.  Primary lymphocytes were 
isolated  from whole blood obtained from healthy volunteers using a Ficoll-Paque Plus method.15  
IRB Protocol #233110-1 approved by the Kansas City University of Medicine and Biosciences 
IRB 04/13/2011. 
Caco-2, MDCK-MDR1 and TZM-bl cells were grown to at least 70% confluence in high-
glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine, and 1% penicillin/streptomycin. J1.1, Jurkat E6-1, and primary 
lymphocytes were grown in RPMI medium (Mediatech, Manassas, VA).  All cells were 
maintained at 37oC in humidified 5% CO2 with fresh medium replaced every 2 to 3 days.      
Virus Production and Quantification 
 J1.1 cells were induced to produce HIV-1 with 10ng/ml TNF-α in RPMI at 370C for 48 
hours. The cells were centrifuged at 277g for 10 minutes and the viral supernatant was collected.  
1 x 106 Jurkat E6-1 cells were pelleted by centrifugation at 277g for 10 minutes.  The pellet was 
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resuspended in 500 microliters of J1.1 viral supernatant and plated in a single well of a tissue 
culture grade 24 well plate. After incubating for 1 hour at 37oC and 5% CO2, the Jurkat E6-1 
cells were transferred to 4.5mL of RPMI.  The infected Jurkat E6-1 cells were grown in RPMI at 
37oC and 5% CO2 for seven days.  After seven days, the cells were centrifuged at 277g for 10 
minutes and the viral supernatant removed and stored at -80oC.  
TZM-bl cells were grown in DMEM at 37oC until 70% confluent. Then, TZM-bl cells 
were diluted to 2 x 105 cells/ml using DMEM with 1,000x DEAE Dextran.  The virus solutions 
were diluted to 1:5, 1:25, 1:125, 1:625 and aliquoted to 96 well tissue culture grade plates. 50 
microliters TZM-bl cells (2 x 105 cells/ml) were added to each well and the plate was incubated 
at 37oC for 48 hours. After 48 hours, media was removed and fixing solution [1% Formaldehyde, 
0.2% gluteraldehyde, 1X PBS] was added to each well for 5 minutes. Cells were washed with 1X 
PBS and stained for one hour at room temperature using staining solution [1X PBS, 0.004M 
Potassium ferrocyanide, 0.004M Potassium ferricyanide, 0.002M MgCl2, 0.53 μg/μl X-gal in 
DMSO (Sigma-Aldrich)]. Cells were washed with 1X PBS and virus was quantified by counting 
the number of -galactosidase positive cells cells per 40x magnified field and using the 
following equation: 
g         . 
Cell Co-Culture Configuration 
 The intestinal model used for this study consisted of both Caco-2 cells (an intestinal 
enterocyte model) and primary lymphocytes separated by a permeable membrane (Figure 1).  
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Figure 1.  Co-culture model used to mimic the relationship between the intestinal endothelial cells 
and the lymphoid cells of the GI reservoir. Caco2 cells representing intestinal endothelial cells were 
grown to confluence on a permeable support in the top compartment of the Transwell plate. Primary 
lymphocytes were obtained from healthy volunteers and grown in RPMI media in the lower compartment. 
 
The Caco-2 cells were plated at a density of 6x104 cell/mL on a 12 Well Transwell (Corning 
Inc., Corning, NY) permeable support (0.4μm Polycarbonate). After 21 days of culturing the 
Caco2 cells on the membranes, media was changed from DMEM to RPMI.  At this time, 
lymphocytes were isolated (see Lymphocyte Isolation/Activation section below) from whole 
blood and then cultured in suspension on the bottom compartment of the Transwell.  
Lymphocyte Isolation/ Activation 
Human lymphocytes were obtained via venous blood samples from healthy volunteers. 
Fresh heparinized human blood samples were separated at room temperature using Ficoll-Paque 
Plus (GE-Healthcare) and centrifuged at 400g for 30 minutes with the brake disengaged as 
described previously by Ting (1971).15  The lymphocyte layer was drawn off and washed with 
1X PBS and suspended in RPMI.  Primary lymphocytes were counted using a hemacytometer 
and the cells were plated in the lower compartment of a 12-well transwell plate at a minimum 
 
   
Caco‐2 cells 
Primary Lymphocytes  
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concentration of 3x106 cells/well. Plates for experiments involving co-cultures with resting 
lymphocytes at this point were exposed to HIV (see protocol below), while lymphocytes for 
experiments involving co-cultures with activated lymphocytes were activated with 
phytohaemagglutinin (PHA) (0.002mg/mL) for 48 hours followed by the addition of 50 units/mL 
of IL-2 for the duration of the experiment. See Figure 2 for an overview of experiments 
performed. 
Co‐Culture with Resting Lymphocytes Co‐Culture with Activated Lymphocytes
Lymphocytes LymphocytesCaco2 Cells Caco2 Cells
 
Figure 2: Flow chart indicating experimental flow after lymphocyte isolation. *Experiments 
involving resting lymphocytes and BCRP are ongoing. 
 
Exposure to HIV-1 or HIV Tat 
Caco-2 cells and primary lymphocytes were exposed to HIV by adding the viral 
supernatant at a concentration of 5,000 virions/ml to RPMI media with 1,000x DEAE Dextran. 
Cells were incubated over a time course (6, 18, 24, 48, 96 or 168 hours) at 37oC and 5% CO2. 
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Additional plates of primary lymphocytes were exposed to HIV Tat by adding Tat to RPMI 
media at a final concentration of 0.1 nM (for 24 hours) at 37oC and 5% CO2.  A time course with 
multiple time points and multiple concentrations of Tat was performed and treatment using 
0.1nM Tat for 24 hours was selected as the time and concentration where Tat had the optimal 
effect (data not shown). 
Cell Lysis of Lymphocytes and Caco2 Cells for Protein Content 
 To isolate total protein from the lymphocytes and Caco2 cells, cells were lysed at the 
designated time points (6, 18, 24, 48, 96, 168 hours) of a seven day time course.  At each time 
point, primary lymphocytes were washed with 1X PBS and centrifuged at 600g for 10 min at 
room temperature to pellet cells. The supernatant was discarded and pelleted cells were 
resuspended in a NP40 lysis buffer [1% Igepal Ca-630 (Sigma-Aldrich), 150 mM Sodium 
Chloride (Thermo Fisher), 50mM Tris (Avantor, Center Valley, PA) HCl (EMD)pH 7.5, Sodium 
Hydroxide (EMD, Gibbstown, NJ) as needed to achieve pH of 8.0] and 1X Complete Protease 
Inhibitor (Roche, Mannheim, Germany). Caco2 cells were washed with 1X PBS and lysed on the 
tissue culture plate by scraping cells in the lysis buffer off the Transwell membrane with a cell 
spatula. Both lymphocytes and Caco2 cells were incubated for 5 minutes on ice, sonicated for 2-
3 seconds, centrifuged at 18,188g (4oC, 10 min) and stored at -80oC. Total protein was quantified 
using BCA Protein Assay Kit (Pierce/Thermo). 
Analysis of Protein Expression 
To examine the effects of HIV infection and Tat exposure on the expression on drug 
efflux proteins in primary lymphocytes and enterocytes (Caco2 cells), we examined P-
glycoprotein and BCRP expression via Western blotting using the methodology described below 
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(Immunoblotting) with primary antibodies for P-glycoprotein, BCRP, and β-actin.  To measure 
oxidative stress in Tat treated samples we used primary antibodies for Peroxiredoxin-SO3, 2-
Cys-Peroxiredoxin. Peroxiredoxin is a collective term for a family of peroxidases (22-27kDa) 
that catalyze the reduction of hydrogen peroxide through the reactive Cys residues of the 
enzymes.16 2-cys-peroxiredoxin (2-cys-Prx) acts as a flood gate protecting cells against peroxide 
substances such as H2O2.
17  However, under high levels of oxidative stress, 2-cys-peroxiredoxin 
can be overoxidized to the sulfonic form (PrxSO3).
17  With this conversion, the peroxidase 
activity of the peroxiredoxin is lost18 and cells become susceptible to severe damage from 
peroxide molecules.  Increased or altered distribution of peroxiredoxin proteins has been used as 
a marker for intracellular oxidative stress in studies of Parkinson’s, Alzheimers, and other 
conditions.16, 19, 20 
Immunoblotting  
Protein expression was analyzed using Western blotting. For each sample, 30μg of total 
cellular protein in Laemmli Buffer [125mM Tris-HCL ph 6.8, 2mM EDTA (Sigma-Aldrich), 4% 
SDS (Avantor), 50% glycerol (Life Technologies), and 0.02% bromphenol blue(EMD) and 10% 
2-Mercaptoethanol(Sigma-Aldrich)] was resolved with electrophoresis on a 12% Novex Tris-
HCL gel (Life Technologies) with a 1X Tris-Glycine SDS running buffer and transferred onto 
Immoblion-P polyvinylidene difluoride (PVDF) 0.45um pore membranes (Millipore, Billerica, 
MA). Membranes were blocked for one hour at room temperature in 5% nonfat milk solution [2g 
of milk + 40ml 0.1% TTBS (0.025M Tris pH7.5, 0.15M NaCl, 0.1% Tween 20(Avantor)]. Then, 
membranes were incubated overnight at 4oC with primary antibody diluted to the appropriate 
concentration in 3% Bovine Serum Albumin (BSA) (EMD) and 0.1% Na Azide in TTBS for the 
following proteins: P-glycoprotein, BCRP, β-Actin, Peroxiredoxin-SO3 and 2-Cys-
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Peroxiredoxin. Primary antibody information is summarized in Table 2. Blots were then 
incubated for one hour at room temperature with the horseradish peroxidase-conjugated anti-
mouse (1:10,000 dilution in 5% nonfat milk/TTBS solution) secondary antibody. Signals were 
enhanced with chemiluminescence using SuperSignal West Dura System (Pierce/Thermo Fisher 
Scientific, Waltham, MA) and detected by exposure to Premium X-Ray Film (Phenix Research 
Products, Candler, NC). The chemiluminescence signal intensity was quantified using an Epson 
Expression 10,000 XL scanner and ImageJ software (NIH).  
Table 2: Summary of primary and secondary antibodies used in western blot experiments 
Primary 
Antibody  
Protein 
Size 
(kD) 
Company Dilution  Secondary 
Antibody  
Company  Dilution  
       
C219 
Monoclonal 
Antibody, 
Purified 
170 Covance 
(Princeton, 
NJ) 
1:200 Anti-mouse 
IgG, HRP-
linked 
Antibody 
Cell 
Signaling 
(Danvers, 
MA) 
1:10,000 
       
Breast Cancer 
Resistance 
Protein 
(human), mAb 
(BXP-21) 
72 Enzo Life 
Sciences 
(Farmingdal
e, NY) 
1:50 Anti-mouse 
IgG, HRP-
linked 
Antibody 
Cell 
Signaling 
(Danvers, 
MA) 
1:10,000 
       
Monoclonal 
Anti-β-Actin 
Clone AC-15 
42 Sigma-
Aldrich (St. 
Louis, MO) 
1:100,00
0 
Anti-mouse 
IgG, HRP-
linked 
Antibody 
Cell 
Signaling 
(Danvers, 
MA) 
1:10,000 
       
Anti-
Peroxiredoxin-
SO3 antibody 
[10A1] 
25 abcam 
(Cambridge, 
MA) 
1:200 Anti-mouse 
IgG, HRP-
linked 
Antibody 
Cell 
Signaling 
(Danvers, 
MA) 
1:10,000 
       
Anti-
2CysPeroxiredo
xin antibody 
[6E5] 
22 abcam 
(Cambridge, 
MA) 
1:1,000 Anti-mouse 
IgG, HRP-
linked 
Antibody 
Cell 
Signaling 
(Danvers, 
MA) 
1:10,000 
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Data Analysis 
Scatter plots of all available data were generated with mean relative protein expression of 
repeated trials with standard error of the mean error bars.  Predictive curves were generated and 
area under the curve (AUC) was calculated by the trapezoidal rule using SigmaPlot 12.0. Time 
courses were excluded from AUC calculations if data was missing from critical time points. 
Results are reported as the mean AUC with standard deviation and 95% confidence intervals.  
Wilcoxon Rank Sign Tests were performed to compare control AUCs to AUCs of HIV infected 
samples. To test for an increase in P-glycoprotein, BCRP and peroxiredoxin sulfate expression in 
response to Tat exposure one-tailed, paired Students t-tests were conducted between each 
treatment group and the appropriate control. Baseline criterion for statistical significance was p < 
0.05. 
Results 
In this study we examined the effects of HIV infection on the expression of P-
glycoprotein and BCRP in an in vitro co-culture model of the human intestinal tract.  
Additionally we investigated the role of the HIV protein Tat as a potential mechanism for 
observed changes in drug efflux protein expression.  
HIV Effects on P-glycoprotein and BCRP Expression in Primary Lymphocytes 
Time course experiments (6 time points over 7 days) were performed using isolated 
lymphocytes grown in co-culture with Caco2 cells exposed to HIV.  Lymphocyte and Caco2 cell 
lysates from each time point were analyzed for P-glycoprotein and BCRP expression.  Five time 
course experiments were completed with co-cultures of activated lymphocytes and three 
complete time course experiments were completed with co-cultures of resting lymphocytes.  We 
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detected P-glycoprotein protein expression in isolated primary lymphocytes and Caco2 cells at 
approximately 170kDa using the mouse monoclonal antibody C219, raised against an internal 
epitope of human P-glycoprotein.  MDCK-MDR1 cell lysate was used as a positive control for 
P-glycoprotein expression.  BCRP expression was detected in isolated primary lymphocytes and 
Caco2 cells at approximately 72kDa using the mouse monoclonal antibody BXP-21.  Lysate 
from high passage number (p50) Caco2 cells was used as a positive control.  Samples were 
normalized for protein concentration using β-actin (42kDa) with a mouse monoclonal antibody 
(Figure 3).   
 
Figure 3: Representative Blot of P-glycoprotein and BCRP Expression in Primary Lymphocytes 
Exposed to HIV A representative blot of P-glycoprotein and BCRP expression from HIV infected, 
activated primary lymphocytes. MDCK-mdr1 cell lysate and high passage number Caco2 cells (P50) were 
used as positive controls for P-glycoprotein and BCRP, respectively.  β-actin was used to normalize. 
 
The blots represented in Figure 3 were quantified for relative P-glycoprotein expression, 
as were blots from experiments with resting lymphocytes and results are shown in Figure 4.  
Three to five time courses, with triplicate replicates at each time point, were analyzed for 
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experiments. Results are shown as the mean P-glycoprotein expression (normalized to β-actin) 
with standard error bars. Predictive curves were calculated to fit the data points.  Overall, 
exposure to HIV resulted in an increased expression of P-glycoprotein in both the activated 
primary lymphocytes as well as resting lymphocyte experimental groups (Figure 4).  Data for all 
experiments is summarized in Table 3, including the mean area under the curve (AUC) for P-
glycoprotein expression in HIV infected activated lymphocytes which was 108.28 (95% CI 
98.97-117.59) was higher than the control mean AUC of 54.52 (95% CI 24.49-84.54). A similar 
observation of a lesser magnitude was found in resting lymphocytes.  P-glycoprotein expression 
AUC in HIV infected non-activated lymphocytes was 79.32 (95% CI -43.50 – 202.13) similar to 
that in the control group which had a mean AUC of 63.05 (95% CI 11.61-114.50). 
 
Figure 4: Analysis of P-glycoprotein Expression in Primary Lymphocytes in Response to Exposure 
with HIV Analysis from Western Blots revealing relative P-glycoprotein expression (normalized to β-
actin) in activated primary lymphocytes cultured in a co-culture configuration with Caco2 cells. Panel A 
represents activated lymphocytes from the co-culture. Panel B represents resting lymphocytes from the 
co-culture. Graphs represent means from a minimum of 3 separate experiments (each performed in 
triplicate) with standard error bars.  
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Table 3 Area under the curve (AUC) summary data from co-culture experiments involving primary 
lymphocytes and Caco2 cells.  Data represent mean AUC 2-3 complete time course experiments with 
standard deviation (St. Dev.) and 95% confidence intervals (CI). 
  AUC Control AUC HIV p-value 
Lymphocytes Mean St.Dev. 95% CI Mean St.Dev. 95% CI  
P-
glycoprotein 
Expression in 
Activated 
Lymphocytes 
54.52 15.32 (24.49 - 84.54) 108.28 4.75 (98.97 - 117.59) 0.1250/0.125 
 
P-
glycoprotein 
Expression in 
Resting 
Lymphocytes 
63.05 26.25 (11.61 - 114.50) 79.32 62.66 (-43.50 - 202.13) 1.0000 
               
BCRP 
Expression in 
Activated 
Lymphocytes 
24.72 0.11 (24.52 - 24.93) 43.47 3.42 (36.76 - 50.18) 0.5000/0.2500
               
Caco2 Cells              
P-
glycoprotein 
Expression in 
Caco2 cells 
co-cultured 
with 
Activated 
Lymphocytes 
203.66 114.07 
(-19.91 - 
427.24) 
265.05 109.67 (50.11 - 480.00) 
0.2500/0.0625
 
P-
glycoprotein 
Expression in 
Caco2 cells 
co-cultured 
with Resting 
Lymphocytes 
156.43 51.18 (56.12 - 256.73) 164.86 28.52 (108.97 - 220.76) 1.0000 
               
BCRP 
Expression in 
Caco2 cells 
co-cultured 
with 
Activated 
Lymphocytes 
338.65 21.02 
(297.44 - 
379.85) 
383.65 12.88 (358.41 - 408.89) 0.5000/0.2500
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An increase in the expression of BCRP was observed in HIV infected activated 
lymphocytes compared to uninfected controls at all time points (Figure 5).  The mean AUC for 
BCRP expression in HIV infected activated lymphocytes was 43.47 (95% CI 36.76 – 50.18) 
which is greater than the mean AUC of control samples [24.72 (95% CI 24.52-24.93)] (Table 3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Analysis of BCRP Expression in Primary Lymphocytes in Response to Exposure with 
HIV Analysis from Western Blots revealing relative BCRP expression (normalized to β-actin) in 
activated primary lymphocytes culture in a co-culture configuration with Caco2 cells.   
 
HIV Effects on P-glycoprotein and BCRP in Caco2 Cells  
To determine if the HIV-induced increase in drug efflux protein expression was exclusive 
to the lymphocytes in our model system, we examined the expression of P-glycoprotein and 
BCRP in Caco2 cells grown in co-culture with isolated lymphocytes.  We did not anticipate 
significant increases in the expression of these drug efflux pumps in the Caco2 cells, as this 
would impede normal drug absorption into circulation.  We detected and analyzed protein 
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expression of P-glycoprotein and BCRP in HIV exposed Caco2 cells (Figures 6). The protein 
expression was quantified and normalized for loading using β-actin as described above. 
Figure 6: Representative Blot of P-glycoprotein and BCRP Expression in Caco2 Cells Exposed to 
HIV A representative blot of P-glycoprotein and BCRP expression from HIV exposed Caco2 cells. 
MDCK-mdr1 cell lysate and high passage number Caco2 cells (P50) were used as positive controls for P-
glycoprotein and BCRP, respectively.  β-actin was used to normalize. 
 
Similar to lymphocytes, we analyzed the expression of P-glycoprotein and BCRP in 
Caco2 cells in response to HIV when grown in co-culture with activated and resting primary 
lymphocytes (Figure 7).  The mean AUC for P-glycoprotein expression in Caco2 cells grown in 
co-culture with activated lymphocytes was 265.05 (50.11 – 480.00) compared to the control 
mean AUC of 203.66 (95% CI -19.91-427.24).  In Caco2 cells grown in co-culture with resting 
lymphocytes, P-glycoprotein expression AUC in HIV infected samples was 164.86 (95% CI -
108.97 – 220.76) compared to the control group which had a mean AUC of 156.43 (95% CI 
56.12-256.73) (Table 3). 
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Figure 7: Analysis of P-glycoprotein Expression in Caco2 cells in Response to Exposure with HIV 
Analysis from Western Blots revealing P-glycoprotein expression (normalized to β-actin) in Caco2 cells 
grown in co-culture with primary lymphocytes. Panel A represents Caco2 cells grown in co-culture with 
activated lymphocytes. Panel B represents Caco2 cells grown in co-culture with resting lymphocytes. 
Graphs represent means from a minimum of 3 separate experiments (each performed in triplicate) with 
standard error bars. 
 
BCRP expression within Caco-2 cells grown in co-culture with activated lymphocytes 
does not appear to be altered upon exposure to HIV (Figure 8).  The mean AUC for BCRP 
expression in HIV infected samples was 383.65 (95% CI 358.41-408.89).  The mean AUC for 
BCRP expression in the control group was 338.65 (95% CI 297.44-379.85) (Table 3).   
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Figure 8: Analysis of BCRP Expression in Caco2 cells  in Response to Exposure with HIV 
Analysis from Western Blots revealing relative BCRP expression (normalized to β-actin) in Caco2 cells 
grown in co-culture with activated primary lymphocytes.  Graphs represent data from 3 separate 
experiments (each performed in triplicate). 
 
Relative Drug Efflux Pump Expression in Response to HIV-1 Tat Exposure  
In order to investigate a potential mechanism of the upregulation of drug efflux proteins 
observed in response to HIV, we examined the effects of exposure to HIV-1 Tat on P-
glycoprotein and BCRP expression in lymphocytes.  In response to 0.1nM Tat exposure for 24 
hours, P-glycoprotein expression in resting lymphocytes increased by 43% (p <0.05) at 24 hours 
(0.1nM Tat) (Figure 9).   
 
 
 
 
 
Time (hours)
0 24 48 72 96 120 144 168
B
C
R
P
/
-a
ct
in
 r
a
tio
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Control
HIV
21 
 
 
 
 
 
Figure 9: Exposure to Tat increases P-glycoprotein Expression in Primary Lymphocytes  
Graph representing resting lymphocytes exposed to 0.1nM Tat for 24 hours, resulting in a 43% increase in 
P-glycoprotein expression (p<0.05) compared to untreated controls. Graphs represent data from 3 
separate experiments (each performed in triplicate). 
 
BCRP expression in resting lymphocytes exposed to 0.1nM Tat for 24 hours was not 
different from unexposed samples (8% increase in Tat-treated lymphocytes, p=0.19) (Figure 10). 
 
Figure 10: Exposure to Tat does not affect BCRP Expression in Primary Lymphocytes  
Graph representing resting lymphocytes exposed to 0.1nM Tat for 24 hours, resulting in no significant 
change in BCRP expression (p>0.05) compared to untreated controls. Graphs represent data from 3 
separate experiments (each performed in triplicate). 
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Expression of Oxidative Stress Marker in Tat-treated Lymphocytes  
Oxidative stress is involved the pathogenesis of HIV21, 22 and HIV-1 Tat is believed to be 
involved in this process.  To examine if the observed increase in P-glycoprotein expression in 
Tat treated cells was associated with increased levels of oxidative stress, we analyzed differences 
in the expression of the protein peroxiredoxin sulfate, a known marker of oxidative stress, 
relative to 2-cys-peroxiredoxin.  Increased ratios of peroxiredoxin sulfate to 2-cys-peroxiredoxin 
are the result of excess over-oxidation of the peroxiredoxin protein, indicating high levels of 
intracellular oxidative stress. We observed the over-oxidized form of the protein peroxiredoxin 
(peroxiredoxin sulfate) at approximately 25kDa using a mouse monoclonal antibody.  We 
expressed this as a ratio of peroxiredoxin sulfate to the less oxidized form of peroxiredoxin (2-
cys-peroxiredoxin) [Prx-SO3 /2-cys-peroxiredoxin].  There was a 27% increase (p=0.26) in this 
marker of oxidative stress in lymphocytes exposed to 0.1nM Tat for 24 hours, although this 
finding was not statistically significant (Figure 11). 
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Figure 11: Oxidative Stress in Tat-treated Primary Lymphocytes Graph shows a non-significant 
increase in levels of oxidative stress in Tat-exposed resting lymphocytes. P-glycoprotein expression was 
normalized to β-actin and peroxiredoxin sulfate, a marker of oxidative stress, expression normalized to 
cys-peroxiredoxin. Graphs represent data from 3 separate experiments (each performed in triplicate). 
 
Discussion 
Conclusions 
  These data demonstrate an increase in P-glycoprotein and BCRP expression in HIV 
infected primary lymphocytes with little effect on the expression of these two efflux pumps in 
Caco-2 cells (enterocytes), in a human intestine model (summarized in Table 30).  Increased 
drug efflux protein expression in primary lymphocytes is an important discovery as this may 
result in decreased antiretroviral accumulation within these cells and thereby limits their 
effectiveness in GI lymphoid tissue.  
P-glycoprotein upregulation in response to HIV infection was observed in both activated 
and resting lymphocytes (Figure 4), which are both important in HIV persistence. Activated 
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lymphocytes, specifically in the lamina propria of the GI tract, are hosts to HIV-infection and 
viral replication.23, 24  Additionally, activated lymphocytes have been shown to be infected with 
higher levels of HIV, when compared with resting lymphocytes in peripheral blood and GI 
lymphoid tissue. 3, 25  Resting lymphocytes are also an important potential contributor to HIV 
persistence as these cells may be a site of residual viral replication26 and/or may allow 
unintegrated viral DNA to persist.27  Despite the lack of integration into the host DNA, 
unintegrated DNA (a 2-long terminal repeat (LTR) circle) is capable of serving as a 
transcriptional template for HIV specific proteins, including Tat, which can instigate cell 
activation, cytokine secretion, and HIV infection27.  Increased expression of the drug transport 
protein P-glycoprotein in activated and/or resting lymphocytes could limit the ability of 
antiretroviral drugs to achieve therapeutic concentrations in these cells and therefore limit their 
effectiveness.   
BCRP expression also was increased in HIV infected activated lymphocytes compared to 
uninfected controls (Figure 5, Table 3).   (Studies of BCRP expression in resting lymphocytes 
and in Caco2 cells grown in co-culture with resting lymphocytes are ongoing.)  Increased 
expression of BCRP could also contribute to decreased accumulation of antiretroviral therapies 
within the lymphoid tissues in the GI tract.  Our finding of increased expression of BCRP in HIV 
infected lymphocytes is consistent with findings in other drug resistant pathologies, including 
several types of leukemias and solid tumors28.  
Although we did not anticipate an increase in P-glycoprotein expression within Caco-2 
cells, we did observe increases in P-glycoprotein expression in both Caco2 cells grown in co-
culture with both resting and activated lymphocytes (Figure 7), although expression from these 
samples had much higher variability than lymphocyte samples. We did not observe a substantial 
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increase in BCRP expression in Caco2 cells co-cultured with activated lymphocytes (Figure 8).  
We did not anticipate any change in the expression of P-glycoprotein or BCRP within the 
enterocytes as any alterations of drug efflux proteins within these cells could alter systemic, not 
localized, antiretroviral exposure. Given the variability of these samples it is difficult to draw 
definitive conclusions. 
Additional investigation revealed that HIV-induced changes in the expression of P-
glycoprotein may be mediated by the HIV protein Tat (Figure 9).   Our finding of increased P-
glycoprotein in lymphocytes in response to treatment with 0.1nM Tat is consistent with Tat’s 
effects on P-glycoprotein in other viral reservoirs.  Tat has been shown to increase promoter 
activity of P-glycoprotein, leading to an increase in the protein’s expression in the endothelium 
of the blood-brain barrier29.  Hayashi et al. (2005) found that exposure to Tat resulted in an 
increase in the expression of P-glycoprotein in an in vitro model of brain microvascular 
endothelial cells10.  The upregulation of P-glycoprotein in the blood brain barrier could 
contribute to lack antiretroviral penetration into the reservoir of the central nervous system.   
However, we did not find an increase in the expression of BCRP in lymphocytes treated 
with Tat compared to controls (Figure 10).  These results suggest that the mechanism for 
increased P-glycoprotein expression in response to HIV infection involves Tat but this 
mechanism does not contribute to the observed upregulation of BCRP in lymphocytes.  
In these experiments, lymphocytes exposed to Tat had higher levels of oxidative stress 
than controls, as indicated by perioxiredoxin sulfate/2-cys-peroxiredoxin ratios (Figure 11).  Tat 
is known to activate inflammatory pathways within cells and increase levels of oxidative stress 
within exposed cells 11, therefore we anticipated an increase in oxidative stress in Tat treated 
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cells.  Our experiments resulted in a 27% increase in perioxiredoxin sulfate/2-cys-peroxiredoxin 
ratio in Tat-treated lymphocytes, however, this difference was not statistically significant.  
Therefore it is likely that additional mechanisms are contributing to the upregulation of P-
glycoprotein we observed in response to Tat exposure.  
 Our study provides new insight and information about the expression of drug efflux 
proteins in Caco2 cells and lymphocytes grown in a co-culture model of the human intestine, but 
it did have some limitations.  Although our data demonstrates an important trend toward an 
increased expression of P-glycoprotein in response to HIV infection in lymphocytes, not all 
results were statistically significant.  To further investigate the implication of our observed trend, 
functional studies should be performed to determine the consequences of altered protein 
expression, specifically if the increases in P-glycoprotein and BCRP expression result in 
increased activity of these proteins and decreased accumulation of antiretrovirals into 
lymphocytes. Many antiretrovirals, especially protease inhibitors, are known to alter the 
expression of drug transport and metabolism proteins (Table 1).  Therefore HIV effects on the 
expression of drug efflux proteins in vivo may be compounded with changes induced by the 
antiretroviral drugs themselves. Finally, although many antiretroviral drugs are substrates for P-
glycoprotein or BCRP, these two proteins are not exclusively responsible for the uptake and 
efflux of drugs used in the treatment of HIV.  Therefore the upregulation of these P-glycoprotein 
and BCRP may not fully explain the potential decrease in penetration of selective antiretroviral 
drugs to reservoir tissues. Future studies should investigate the effects of HIV on other transport 
proteins, including proteins involved in both uptake and efflux of antiretroviral drugs.  
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Summary  
The purpose of this study was to investigate the effects of HIV infection on drug efflux 
protein expression, specifically P-glycoprotein and BCRP, in an in vitro co-culture model of the 
human intestine. Our study found an increase in P-glycoprotein and BCRP expression in HIV-
infected lymphocytes compared to uninfected controls (Figures 4 & 5).  Additionally we 
observed an increase in the expression of P-glycoprotein but no change in the expression of 
BCRP in response to the HIV-1 protein Tat (Figure 9 & 10).  Tat exposure was accompanied by 
increased levels of oxidative stress (Figure 11). Collectively these data represent important 
observations about HIV effects on lymphocytes in a human intestine model. These results 
suggest a mechanism to explain the decreased penetration into lymphoid rich regions of the GI 
tract, an important viral reservoir.  These changes may contribute to the persistence of HIV 
despite treatment with antiretroviral therapy and represent a critical finding in the effort to 
modulate and optimize HIV therapy.  
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Appendix B: Further Background on P-glycoprotein, Breast Cancer 
Resistance Protein, HIV-1 Tat, and Oxidative Stress  
P-glycoprotein 
P-glycoprotein, also called ATP-Binding Cassette B1 (ABCB1), is a transmembrane 
protein encoded for in humans by MDR1 gene.  P-glycoprotein is normally expressed in a 
variety of healthy tissues, including hepatocytes, renal tubular cells, intestinal epithelial cells, 
and lymphocytes, where it serves as an ATP-dependent transporter of toxins, drugs and 
xenobiotics from inside to outside cells, serving a protective function1.  This protective function 
is demonstrated in the placenta where P-glycoprotein and other drug transporters, protect the 
fetus from accumulating toxic agents ingested by the mother during gestation2, 3 and in the blood 
brain barrier where P-glycoprotein prevents drugs from penetrating into the central nervous 
system (CNS).4    
 In addition to this protective function, P-glycoprotein can also prevent beneficial 
therapies from penetrating into specific tissues, thus promoting drug resistance and treatment 
failure in a variety of conditions.  P-glycoprotein was first discovered in tumors displaying drug 
resistant phenotype5 Previous literature has found that P-glycoprotein expression is increased in 
cells that display multidrug resistance phenotypes including solid tumor.5  Drug resistance has 
been linked to high levels of P-glycoprotein expression in neuroblastoma6 and acute 
lymphoblastic leukemia.7  Overexpression of P-glycoprotein has also been hypothesized to 
contribute to drug resistance in epilepsy.8 The wide variety of pathologies influenced by P-
glycoproetin expression is likely due to the vast number of drugs that are substrates for P-
glycoprotein including anticancer drugs, steroids, immunosuppressants, antibiotics, beta-
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blockers, and many more.1  It is important to note that in addition to serving as substrates for P-
glycoprotein, many drugs including calcium-channel blockers, steroids, quinolones, refampicin, 
and immunosuppressive drugs can affect function by inducing and inhibiting P-glycoprotein.5  In 
addition to alterations in function caused by certain drugs, the expression of P-glycoprotein can 
also be influenced by other factors including environmental stress and hormones.   
Specifically of interest for HIV, many of the drugs used to treat HIV (protease inhibitors, 
nucleoside reverse transcriptase inhibitors (NRTIs) and entry inhibitors) are substrates for P-
glycoprotein).  Overexpression of P-glycoprotein in the microvascular endothelium is associated 
with decreased penetration of protease inhibitors and nucleoside reverse transcriptase inhibitors 
into the CNS.9, 10  Additionally upregulation of P-glycoprotein expression has been shown to 
limit the accumulation of protease inhibitors in lymphocytic cell lines.11  Some antiretrovirals are 
also inhibitors and inducers of P-glycoprotein as well,12 complicating the clinical treatment and 
management of HIV infected patients. 
Breast Cancer Resistence Protein (BCRP/ABCG2) 
BCRP, also known as ATP-Binding Cassette G2 (ABCG2), is another drug efflux pump 
and has a similar function to P-glycoprotein.  BCRP is also expressed in healthy tissues including 
gastrointestinal endothelium, placenta, liver, and peripheral blood mononuclear cells (PBMCs) 
including lymphocytes.13 In these tissues, BCRP has a similar role to other drug efflux pumps in 
protecting cells from potentially toxic substances including pharmacological therapies. BCRP 
has also been found to be overexpressed in many resistant cancer lines.14,15  Elevated expression 
of BCRP, in addition to other drug transporters, has been found in a variety of hematologic 
cancers and solid tumors, but BCRP is believed to be uniquely associated with leukemia 
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resistance to flavopirodol and chemotherapy failure in non-small cell lung cancer.15  Although 
BCRP was original discovered in the breast cancer cell line MCF7/AdrVp, multiple studies have 
failed to attribute BCRP expression to drug resistance in breast carcinoma.16, 17   
The specific role of BCRP in HIV therapy is still being investigated, as whether many 
antiretroviral drugs are substrates for BCRP has yet to be studied.  To date, it is known that 
several nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors are substrates 
for BCRP (Table 112, 18).  Additional BCRP substrates include chemotherapy agents, specifically 
mitoxantrone and camptothecin derivates, and organic anions.15   BCRP’s substrate specificity 
overlaps to some extent with that of P-glycoprotein.   
Given the recent discovery by Fletcher et. al that there is decreased antiretroviral 
penetration into the reservoir tissues of the GI tract, it is possible that HIV infection causes an 
upregulation of drug efflux pumps thus preventing antiretroviral therapies from penetrating into 
HIV reservoir tissues.  Studying the relationship between HIV and the drug efflux pumps P-
glycoprotein and BCRP in lymphoid cells of gastrointestinal tract will contribute to better 
understanding of the distribution and penetration of antiretroviral drugs into this important 
reservoir. 
Transactivator of Transcription (Tat) 
 The Transactivator of Trascription (Tat) protein is a HIV-1 specific protein that enhances 
transcription of the virus.  Typically viral proteins can only be transcribed and produced after 
infection, which required viral DNA to be integrated into the host DNA, but Tat has the unique 
capability of being transcribed both prior to and after DNA integration.19  Additionally HIV-
infected cells can secrete Tat in an unconventional method that does not require cell lysis.20 
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These properties make Tat able to affect both infected and uninfected cells. Exogenous Tat has 
been shown to cause numerous bystander effects including activation and apoptosis of uninfected 
T-cells, upregulation of cytokine expression, and chemotaxis of monocytes. 21 Additionally, Tat 
can be detected in the sera of HIV-infected individuals,22 implying biological activity of this 
protein individually and in cooperation with HIV.  
Previous research on Tat and drug efflux pumps has found that Tat exposure can induce 
P-glycoprotein expression in the microvascular endothelial cells that comprise the blood brain 
barrier23.  Whether or not Tat can affect the expression of BCRP has not previously been studied.  
Tat and Intracellular Oxidative Stress 
Oxidative stress is involved the pathogenesis of many conditions including cerebral 
ischemia,24 cancer, inflammation, and HIV. 25, 26  HIV-1 Tat has been implicated as part of this 
process, although the mechanisms through which Tat can cause oxidative stress is not entirely 
understood.  Tat has been shown to increase reactive oxygen species (ROS) levels in neurons25 
and enterocytes27 and it is known that Tat blocks transcription of manganese superoxide 
dismutase and glucose-6-phosphate dehydrogrenase, both enzymes that are involved in pathways 
that maintain intracellular oxidative balance.27, 28   Additionally, Tat has been shown to activate 
oxidative pathways involving nuclear factor-κB (NF- κB),29, 30 which has binding sequences in 
the promoter region of the gene that codes for P-glycoprotein.25 Based on this evidence, it is 
likely that oxidative stress is associated with Tat mediated effects on drug efflux proteins.  
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Abstract 
     Although current therapies for HIV have revolutionized the fight against AIDS, there are still 
many obstacles to overcome.  Current HIV research efforts are focused on developing an HIV 
vaccine, improving pre-exposure prophylaxis, and overcoming barriers to a cure.  This article 
offers a review of recent findings in each of these areas and discusses current HIV research at 
Kansas City University of Medicine and Biosciences.  
Introduction 
Human Immunodeficiency Virus (HIV-1) infection continues to be a global health crisis with 
no cure. Over 60 million people have been infected with HIV and 25 million have died from 
HIV-related causes since the beginning of this epidemic 31 years ago.1  In Missouri over 10,000 
individuals are living with HIV.2  The majority of these cases are located in the state’s two major 
metropolitan areas: Kansas City and St. Louis.  The introduction of highly active antiretroviral 
therapy (HAART) revolutionized the fight against HIV/AIDS.  These interventions have 
significantly decreased the mortality due to HIV infection from the leading cause of death (in 25-
44 year olds) in 1994 to the sixth leading cause of death in the same age group in 2007.3  
Additionally HAART has extended the life expectancy of HIV-positive individuals (diagnosed at 
age 20) from 36 years in the pre-HAART era to nearly 50 years after implementation of 
HAART.4  HAART improves the markers of HIV disease such as decreasing viral load and 
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increasing CD4+ counts. Because of the biological efficacy and the epidemiological benefits, 
HAART has been transformative in the HIV/AIDS epidemic.  However, patients must remain on 
HAART for the duration of their lives because there is currently no cure for the HIV.  HAART 
treatment is also associated with negative health and financial implications. The drugs used in 
the combination therapy can have immediate adverse side-effects such as hypercoaguability and 
hepatotoxicity.5  Additionally, long-term therapy and the extended duration of the disease result 
in a series of debilitating sequelae. These include the development of diabetes mellitus, 
hyperlipidemia, cardiovascular disease, and liver failure.6  Collectively, the adverse effects of the 
drugs and long-term sequelae of the disease can compromise disease management and 
significantly decrease patients’ quality of life.  In addition to the adverse health effects from HIV 
infection and therapy, the cost associated with living with this disease can range from $400-
$3000 per month.7  The majority of expenses are due to high cost of drugs and medical bills. 
These factors result in a significant burden on both individuals with this disease and the health 
care system as a whole and create a need for better solutions for the prevention, treatment, and 
eradication of HIV/AIDS.   
To address this problem, research efforts in the HIV/AIDS field have taken many different 
approaches.  Three important areas of focus are: vaccines, pre-exposure prophylaxis, and 
overcoming barriers to a cure. Research on vaccines and pre-exposure prophylaxis is attempting 
to reduce the number of new infections while barriers to a cure research focuses on eliminating 
HIV from individuals already living with the disease.  This article will briefly present and 
discuss recent developments in each of these three areas of HIV research.    
HIV Vaccine 
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     Creating a HIV vaccine could potentially be the most economical and effective way to 
decrease new infections and make progress towards the ultimate goal of eradicating the virus.  
Vaccination programs have been successful in limiting viral epidemics such as measles and polio 
and have even eliminated viruses like smallpox. Vaccines depend on stable viral antigens to 
stimulate either a humoral or cell-mediated immune response from the host’s immune system.  
Unfortunately, thirty years of work toward creating a viable vaccine for HIV have been largely 
unsuccessful due to the rapid evolution of the error-prone HIV genome.  HIV adapts under 
selective pressure from the hosts’ immune systems and quickly becomes resistant to CD8+ T-
cells and humoral immune defenses.  Most humoral and cell-mediated approaches to HIV 
vaccines have failed in the early stages of development.  Table 1 summarizes a few of the largest 
and most notable trials.  Recently, a string of new successes have brought hope back to the 
search for a HIV vaccine.  In 2009, the RV144 HIV Vaccine Trial in Thailand used a 
combination of methods to stimulate both protective antibody responses and T-cell mediated 
response with a resulting 31% reduction of being infected with HIV in the intention to treat 
group.8  Although these results were far better than any HIV vaccine result to that point, the 
reduction in risk was significantly lower than seen with other similar vaccines such as the HPV 
quadrivalent vaccine, which reduced the intention-to-treat risk of developing HPV genital lesions 
by 66%.9  The risk reduction seen in the RV144 study was also transient and protection was 
highest in groups with the lowest exposure to HIV, suggesting that current HIV vaccines would 
not be as effective in high-risk groups.8 
     The most important outcome of the RV144 study was a new interest in understanding the 
specific mechanisms of how HIV vaccines prevent infection.  Researchers learned from the 
successes and limitations of the RV144 trial and are subsequently designing studies that should 
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be better equipped to investigate the protective mechanisms behind successful HIV vaccines.10  
Once the mechanisms and pharmacokinetics are better understood, the vaccines can be 
redesigned to increase efficacy and duration and hopefully provide better protection for members 
of high-risk groups.  Unfortunately, there are still many unanswered questions and years of 
research left before vaccines can become a reliable option for prevention of HIV infection. 
Pre-exposure Prophylaxis 
    Although recent successes in HIV vaccine research have been promising, Pre-exposure 
Prophylaxis (PrEP) has proven to be a more effective method to reduce the risk of HIV infection 
in high-risk groups.  The rationale of PrEP is that the medications used in HAART are very 
effective in decreasing viral loads could be used to prevent the virus from replicating and 
establishing an infection in healthy individuals, preventing transmission in the event of HIV 
exposure.  Many of the HAART drugs have been shown to have higher concentrations in genital 
tissues where most initial exposure to the virus occurs, thus making them ideal candidates for 
PrEP.11 
     Four major PrEP studies have been published with large samples  and  two more articles are 
in progress (see Table 2).  In the Preexposure Prophylaxis Initiative (iPrEx), a combination oral 
dose of the Nucleoside/tide Reverse Transcriptase Inhibitors (NRTI’s) tenofovir/emtricitabine 
produced a 44% reduction in HIV infection risk in a high-risk men-who-have-sex-with-men 
(MSM) population.12  The TDF2 and PartnersPrEP studies used tenofovir/emtricitabine in 
heterosexual men, women and discordant couples with a resulting 62% reduced risk in the TDF2 
study and 73% reduced risk in the PartnersPrEP study.13, 14  Topical tenofovir has also shown 
promising results with a 39% to 54% reduction in HIV infection risk in women using a vaginal 
gel, with success dependent on adherence rate.15  The lack of effectiveness demonstrated in these 
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studies has led many researchers to argume that HIV vaccination research be abandoned and 
efforts refocused on improving PrEP. 
     Unfortunately, PrEP faces a number of obstacles to practical implementation.  The 
medications used in PrEP (mainly NRTI’s such as tenofovir and emtricitabine) are expensive and 
the cost of using them on a population-wide scale is unrealistic.  Also, the side effects (such as 
renal failure, bone demineralization, hepatic failure, and lactic acidosis) of long-term NRTI 
therapy in healthy individuals could outweigh benefits and decrease compliance.  In addition,  
patients who seroconvert while taking antiretroviral treatment for PrEP could produce drug 
resistant strains.11  Finally, topical tenofovir regimens lower the possibility of side effects and 
viral resistance and have proven successful in women using a vaginal gel, but a large-scale 
program using topical antiretroviral drugs would be expensive and would depend on high rates of 
adherence among participants. 
     The challenges to both HIV vaccine research and PrEP implementation have led to the need 
for a combined approach to preventing initial infection with HIV.  Although HIV vaccines have 
not been effective for protecting high risk groups, the cost is low and can easily be implemented 
across a population.  Combining a vaccine with only modest benefit with a PrEP protocol that 
has been proven successful in high-risk groups, could compensate for low PrEP adherence rates 
and provide the best overall outcomes in preventing initial infection with HIV.  Although 
significant progress has been made in both the HIV vaccine and PrEP fields, much more research 
is needed before these strategies will significantly decrease the number of new HIV infections. 
Barriers to a Cure 
     As previously discussed, HIV currently cannot be cured.  Antiretroviral therapy can reduce 
viral levels in blood plasma below detection by standard assays.  This is called a “functional” 
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cure or remission.  However, if therapy is halted, viral levels quickly rebound and the disease 
progression continues. The goal of much HIV research is to find a “sterilizing” cure, an 
intervention that would result in complete elimination of the virus from the body.  Some known 
barriers to finding a cure for HIV are viral latency in T-cells, residual viral replication and 
anatomical barriers (also called reservoirs).16  
     HIV latency occurs when viral DNA becomes integrated into resting T-cells.  When this 
happens, the virus is able to persist for the life of the cell without actively replicating. 
Antiretroviral therapies target the replication and production of the virus, and therefore, are not 
effective on latent virus. Latency can be the result of HIV-infected activated T-cells returning to 
the resting state or from the direct infection of resting T-cells.17  Latency is maintained, in part, 
because the cells that become infected have a very long life cycle.  Additionally, Smith, 
Wightman and Lewin have proposed that certain biological proteins and substances can 
negatively regulate T-cell activation, thus prolonging the duration of the resting state and 
promoting latency of the virus.18  Activating resting T cells may be potentially beneficial,  thus 
restarting viral replication and allowing the drugs to act on the no-longer-latent HIV. Recent 
studies are using drugs with a variety of mechanisms such as vorinostat and disulfram16 to test 
this theory, but this testing is still in the early stages, and will require further study before 
conclusions can be drawn.    
      In addition to latent virus throughout the body, a subset of virus undergoes low level 
replication (residual replication), which occurs even during “suppressive therapy” of HAART.  
One theory suggests that this low level residual replication occurs in tissues, although that theory 
remains controversial.19 Opponents of the residual replication hypothesis argue that continual 
replication, even at low levels would likely result in the evolution of HIV DNA or RNA, or the 
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development of drug resistance, which has not been conclusively demonstrated to date.  Also, 
low level replication would likely respond to treatment intensification (adding additional 
antiretroviral to an already suppressive regimen).  However, recent intensification trials have 
failed to demonstrate any clinical benefit to increased antiretroviral therapies.19,20  Conversely 
the arguments in favor of residual replication have been supported by recent studies where viral 
concentrations in tissues have shown to be much higher than plasma concentrations.21  
Additionally, the HIV tissue concentrations correlate with immune activation despite treatment 
with HAART.20  Other evidence in support of residual replication is that the virus can be spread 
cell-to-cell without the release of viral particles.  Because this type of infection does not involve 
the viral replication cycle, cell-to-cell infection is not targeted by HAART, which acts on the 
replication and release of viral particles implicated in cell-free infection.22   
     The last major barrier to an HIV cure is anatomical reservoirs including the gastrointestinal 
(GI) tract, brain, genital tract, and lymph nodes.23  These tissues remain infected with HIV 
despite therapy.  Although the mechanism of reservoir maintenance is not well understood, one 
main theory is decreased antiretroviral penetration into reservoir tissues.  This could prevent 
therapeutic concentrations from being achieved at these sites, thus preventing the drugs from 
being effective. Active research in this area is focusing on studying potential mechanisms for 
decreased antiretroviral penetration into reservoir tissues.  Recent evidence has found 
discrepancies in antiretroviral penetration between blood plasma and reservoir tissues.24  There is 
currently a study underway that is examining penetration of antiretroviral agents into lymph 
tissues with results pending.21   
HIV Research at KCUMB 
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     At the Kansas City University of Medicine and Biosciences (KCUMB), we are looking at 
mechanisms contributing to decreased antiretroviral penetration into the gastrointestinal 
reservoir. Many antiretroviral drugs are transported into and out of cells by various drug 
transport proteins.  The ATP-binding cassette protein P-glycoprotein is responsible for limiting 
drug accumulation within a variety of cell types including lymphocytes, intestinal epithelial cells, 
hepatocytes, and renal tubular cells. 
     Current HIV research at KCUMB is centered around the effects of HIV infection on the 
expression of P-glycoprotein within an in vitro model of the lymphocyte rich reservoir region of 
the gastrointestinal tract. Many antiretroviral drugs are substrates for P-glycoprotein. Therefore, 
dysregulation of this protein could affect the distribution and penetration of these agents into 
certain tissues. Specifically we are looking at P-glycoprotein expression in response to HIV 
infection within enterocytes and lymphocytes. Preliminary results suggest an upregulation of P-
glycoprotein in HIV infected lymphocytes, which could therefore serve to limit drug penetration 
into the gut reservoir tissue and allow HIV to persist. These initial results warrant further 
investigation and contribute to our understanding of a potential mechanism that contributes to 
HIV reservoir maintenance.  Our future studies will compare antiretroviral concentrations in the 
gastrointestinal tract of HIV infected individuals with plasma concentrations of these drugs to 
determine if a discrepancy exists.  
Conclusion 
     Although the field of HIV/AIDS research is making strides to prevent new HIV infections 
and eradicate the virus, HIV/AIDS continues to be a devastating pandemic.  More research needs 
to be done to discover effective methods to eliminate HIV/AIDS.  A number of advancements 
have been made to develop HIV vaccines, improve pre-exposure prophylaxis, and overcome 
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other barriers to curing HIV.  Specifically at KCUMB, we are focused on better understanding 
the viral reservoir of the gastrointestinal tract, and the role that drug transport proteins and drug 
distribution may play in the maintenance of this reservoir.  With a multi-faceted approach to 
HIV/AIDS research, prevention, and treatment, the research community can continue to make 
small steps toward making HIV/AIDS a disease of the past. 
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Pgp Area
Beta-actin 
Area
Relative 
area Pgp Area
Beta-actin 
Area Relative area
6- 33575.078 44858.241 0.7484707 6- 16390.38 21898.329 0.748476288
6+ 43593.2 46434.413 0.9388123 6+ 18923.915 21761.572 0.869602389
18- 33765.3 39156.22 0.8623228 18- 10624.48 21891.016 0.485335171
18+ 50393.22 37600.099 1.3402417 18+ 12146.723 23429.966 0.51842683
24- 32468.886 29984.321 1.0828621 24- 26156.815 27809.401 0.940574556
24+ 46875.806 33207.149 1.4116179 24+ 12266.43 24518.037 0.500302288
48- 34068.2 41961.22 0.8118973
48+ 44710.806 45789.756 0.9764369
96- 33583.2 32595.271 1.030309
96+ 38570.321 32836.463 1.1746186
Pgp Area
Beta-actin 
Area
Relative 
area Pgp Area
Beta-actin 
Area Relative area
6- 15508.886 54213.978 0.286068 6- 8589.652 47128.099 0.182261797
6+ 15987.865 52109.028 0.3068156 6+ 23411.007 43026.492 0.544106803
18- 25621.664 56512.978 0.4533766 18- 21061.229 48013.534 0.438651923
18+ 35705.563 54687.149 0.6529059 18+ 38563.563 44920.614 0.858482544
24- 31188.028 56210.685 0.5548416 24- 39145.593 47172.735 0.829835137
24+ 36804.128 56839.291 0.6475121 24+ 29326.007 44401.907 0.660467286
48- 11722.359 58220.291 0.2013449 48- 34584.078 49969.969 0.692097247
48+ 35008.472 57828.927 0.6053799 48+ 34126.25 54633.806 0.624636146
96- 22133.522 57554.907 0.3845636 96- 17786.714 64558.848 0.275511639
96+ 48176.421 54860.492 0.8781624 96+ 32070.886 49616.028 0.646381568
168- 17582.815 55824.806 0.3149642 168- 13135.329 46233.584 0.284107955
168+ 29072.856 56730.099 0.5124767 168+ 39646.593 48437.099 0.818517083
Pgp Area
Beta-actin 
Area
Relative 
area
6- 2008.619 35396.865 0.0567457
6+ 4443.246 42488.543 0.1045752
18- 29292.35 39401.522 0.7434319
18+ 25516.622 43802.957 0.582532
24- 2074.912 37099.643 0.0559281
24+ 28544.087 41072.986 0.6949601
48- 2802.033 39282.472 0.0713304
48+ 13428.187 42364.643 0.3169668
96- 1600.669 46503.472 0.0344204
96+ 39500.007 48671.765 0.811559
168- 33496.936 46201.128 0.7250242
168+ 33393.057 45453.421 0.7346654
Experiment #2
Activated Lymphocytes Probed for P-glycoprotein
Experiment #1
Experiment #3 Experiment #4
Experiment #5
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Pgp Area
Beta-actin 
Area
Relative 
area Pgp Area
Beta-actin 
Area Relative area
48- 5775.56 36638.815 0.157635 48- 37627.64 37473.47 1.00411414
48+ 16493.773 32447.572 0.5083207 48+ 38984.37 36877.69 1.05712608
96- 17925.48 45218.614 0.3964182 96- 14199.5 33315.74 0.42620993
96+ 26392.43 47190.856 0.55927 96+ 34352.77 32645.33 1.05230261
Pgp Area
Beta-actin 
Area
Relative 
area Pgp Area
Beta-actin 
Area Relative area
48- 37330.59 32109.99 1.162585 48- 51814.51 35204.35 1.47182132
48+ 27285.26 34103.33 0.800076 48+ 46313.76 39361.74 1.1766185
96- 27870.62 31695.04 0.879337 96- 39765.49 33645.92 1.18188172
96+ 37130.16 36308.77 1.022622 96+ 42492.53 32239.67 1.31802001
Pgp Area
Beta-actin 
Area
Relative 
area Pgp Area
Beta-actin 
Area Relative area
6- 5563.267 18599.409 0.2991099 6- 10901.38 17253.217 0.631846223
6+ 1344.163 20400.187 0.0658897 6+ 10443.48 18196.217 0.573936879
18- 12353.137 24279.066 0.5087979 18- 11593.258 15135.853 0.765946789
18+ 12333.137 22274.409 0.5536909 18+ 23991.957 19767.217 1.213724572
24- 2138.376 21941.702 0.0974572 24- 5922.217 18351.095 0.322717364
24+ 14416.794 25743.238 0.5600226 24+ 18170.451 20868.167 0.870725781
48- 23582.057 24428.238 0.9653605 48 - 16330.986 20199.53 0.808483465
48+ 18390.572 25998.238 0.7073776 48 + 16921.279 19441.995 0.870346845
96- 14186.501 23670.409 0.5993348 96- 28408.907 16366.581 1.735787517
96+ 26455.179 28581.723 0.9255978 96+ 10905.208 19920.681 0.547431486
168- 11413.894 21842.167 0.5225623 168- 20061.643 18647.146 1.075855951
168+ 21313.472 20651.167 1.0320711 168+ 38201.664 15251.146 2.504838915
Pgp Area
Beta-actin 
Area
Relative 
area Pgp Area
Beta-actin 
Area Relative area
6- 28784.279 16638.388 1.7299921 24- 35376.555 26888.815 1.315660619
6+ 19682.38 19079.874 1.0315781 24+ 37809.99 31063.593 1.217180189
18- 23547.179 18576.752 1.2675617 24- 25944.827 31675.957 0.819070028
18+ 15852.551 20681.652 0.7665031 24+ 39321.697 37782.907 1.040727147
24- 25548.35 19723.874 1.2953008 24- 24355.806 45087.685 0.540187548
24+ 21520.401 21818.995 0.986315 24+ 28026.777 35168.836 0.796920802
48- 18582.501 20342.045 0.9135021
48+ 20756.622 23029.288 0.9013141
96- 20193.108 19776.045 1.0210893
96+ 22219.501 19588.045 1.1343399
168- 20977.037 15399.024 1.3622316
168+ 23529.744 16142.267 1.457648
Experiment #1 Experiment #2
Experiment #3 Experiment #4
Experiment #5 Experiment #6
Experiment #7 Experiment #8
Caco2 Cells Grown in Co-culture with                                                 
Resting  Lymphocytes Probed for P-glycoprotein
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eriment #1 Experiment #2
Bxp-21 
Area
Beta-actin 
Area
Relative 
area
BXP-21 
Area
Beta-actin 
Area
Relative     
area
6- 6830.903 44858.241 0.1522775 6- 4657.681 21898.33 0.21269573
6+ 9828.803 46434.413 0.2116707 6+ 5430.167 21761.57 0.24953009
18- 8399.439 39156.22 0.214511 18- 4457.903 21891.02 0.20364075
18+ 20281.986 37600.099 0.5394131 18+ 12377.09 23429.97 0.52825885
24- 4228.125 29984.321 0.1410112 24- 7107.238 27809.4 0.25556962
24+ 10992.167 33207.149 0.3310181 24+ 9193.43 24518.04 0.37496599
48- 10941.258 41961.22 0.2607469
48+ 15483.501 45789.756 0.3381433
96- 7770.995 32595.271 0.2384087
96+ 13441.108 32836.463 0.4093348
Experiment #3 Experiment #4
BXP-21 
Area
Beta-actin 
Area
Relative 
area
BXP-21 
Area
Beta-actin 
Area
Relative     
area
6- 49307.06 14402.65 3.423471 6- 1209.426 35396.87 0.0341676
6+ 51997.35 16968.19 3.064402 6+ 3100.175 42488.54 0.07296496
18- 50586.11 22238.92 2.274666 18- 9164.238 39401.52 0.23258589
18+ 54839.94 20658.33 2.654616 18+ 11464.36 43802.96 0.26172569
24- 40239.43 15708.89 2.56157 24- 7025.995 37099.64 0.18938174
24+ 47001.82 14921.36 3.149969 24+ 13238.14 41072.99 0.32230764
48- 46647.55 20885.5 2.233489 48- 6233.409 39282.47 0.15868169
48+ 37965.18 20157.38 1.883438 48+ 11930.57 42364.64 0.28161625
96- 35905.4 18562.97 1.934249 96- 6285.752 46503.47 0.13516737
96+ 52403.13 23576.45 2.22269 96+ 13978.87 48671.77 0.28720686
168- 38542.97 17877.65 2.15593 168- 7296.409 46201.13 0.15792707
168+ 56003.63 19753.84 2.835075 168+ 7640.995 45453.42 0.16810605
Activated  Lymphocytes Probed for BCRP
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Experiment #1 Experiment #2
Pgp Area
Beta-actin 
Area Relative area Pgp Area
Beta-actin 
Area Relative area
6- 15353.229 20699.409 0.741723061 6- 8133.602 8324.974 0.977012301
6+ 31268.22 22579.359 1.384814334 6+ 24817.79 9079.803 2.733295535
18- 31907.392 20593.187 1.549414959 18- 11321.92 10482.56 1.080071566
18+ 38065.291 23796.773 1.599598862 18+ 28340.22 15950.995 1.776705466
24- 25046.371 21500.066 1.164943912 24- 20383.08 14793.995 1.377794031
24+ 23112.128 22648.773 1.020458283 24+ 22421.15 14674.652 1.527882842
48- 10683.258 24739.309 0.431833322 96- 24717.32 14388.217 1.717886309
48+ 16938.279 19766.48 0.85691934 96+ 26865.98 10005.974 2.684993785
96- 26394.735 22499.673 1.173116383
96+ 13306.794 20279.43 0.656171993
Experiment #3 Experiment #4
Pgp Area
Beta-actin 
Area Relative area Pgp Area
Beta-actin 
Area Relative area
6- 8853.945 27294.43 0.324386514 6- 25664.17 14402.652 1.78190586
6+ 21505.664 31635.794 0.679788976 6+ 37156.89 16968.187 2.189797236
18- 21475.421 31377.43 0.684422561 18- 41215.04 22238.915 1.853284659
18+ 28946.664 32180.208 0.899517617 18+ 40956.12 20658.329 1.982547717
24- 26563.25 35868.622 0.740570686 24- 46408.48 15708.894 2.954280804
24+ 31855.472 35195.794 0.905093148 24+ 48737.07 14921.359 3.266262141
48- 6220.974 24826.652 0.250576437 48- 31009.05 20885.501 1.48471655
48+ 25036.158 22139.874 1.130817547 48+ 37481.88 20157.38 1.859461746
96- 13473.48 19030.217 0.708004538 96- 34789.51 18562.966 1.87413547
96+ 2197.79 22351.217 0.098329769 96+ 48198.84 23576.451 2.044363632
168- 11103.48 19473.681 0.570178797 168- 40587.24 17877.652 2.270278054
168+ 31109.572 15415.024 2.018133219 168+ 49613.43 19753.844 2.511583315
Experiment #5
Pgp Area
Beta-actin 
Area Relative area
6- 11543.016 16583.309 0.696062288
6+ 39728.057 19264.794 2.06221032
18- 30748.673 19160.208 1.604819374
18+ 38573.007 20855.401 1.849545209
24- 45717.957 23001.329 1.987622411
24+ 49399.463 21417.279 2.306523765
48- 23791.057 16112.501 1.476558915
48+ 41079.401 17657.037 2.326517241
96- 18226.229 19718.158 0.924337304
96+ 41352.765 23491.936 1.760296171
168- 26615.451 22086.744 1.205041857
168+ 23588.936 22857.865 1.031983346
Caco2 Cells Grown in Co-culture with                                             
Activated Lymphocytes Probed for P-glycoprotein
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Pgp Area
Beta-actin 
Area Relative area Pgp Area
Beta-actin 
Area Relative area
48- 2682.912 18219.49 0.14725506 48- 446.749 41656.56 0.01072458
48+ 14052.02 24183.22 0.58106512 48+ 463.849 48735.74 0.00951764
96- 8547.054 20359.32 0.41981045 96- 2019.21 53208.32 0.03794905
96+ 11971.61 19697.61 0.60776967 96+ 1220.48 49190.15 0.02481141
Pgp Area
Beta-actin 
Area Relative area Pgp Area
Beta-actin 
Area Relative area
48- 177.021 40351.42 0.00438698 48- 10693.5 44674.25 0.2393663
48+ 1458.527 39332.94 0.03708157 48+ 17668.6 47384.49 0.37287731
96- 10543.12 44115.96 0.23898645 96- 4178.83 47272.91 0.08839803
96+ 1542.598 40589.4 0.03800495 96+ 9210.02 50870.37 0.18104889
Pgp Area
Beta-actin 
Area Relative area Pgp Area
Beta-actin 
Area Relative area
6- 100.95 17579.65 0.00574243 6- 28.95 17611.82 0.00164378
6+ 4918.56 17720.14 0.27756896 6+ 28.95 23716.97 0.00122065
18- 332.092 19779.48 0.01678972 18- 565.092 26798.92 0.02108638
18+ 569.506 23729.26 0.02400016 18+ 1445.06 30625.69 0.04718463
24- 8450.116 27838.92 0.30353611 24- 1111.41 28935.67 0.03840954
24+ 29654.17 26109.57 1.13575856 24+ 4358.78 28271.74 0.1541745
48- 26589.13 34920.35 0.76142215 48 - 652.335 24205.16 0.02695025
48+ 19033.52 26426.79 0.72023576 48 + 8361.95 32478.06 0.25746445
96- 22534.77 28082.45 0.80245008 96- 20929.3 31134.99 0.67221164
96+ 28560.01 29472.57 0.9690368 96+ 6940.82 28030.55 0.24761636
168- 478.92 13069.22 0.03664489 168- 1133.13 16893.17 0.06707647
168+ 3995.276 6970.761 0.57314775 168+ 1419.06 6276.711 0.22608369
Pgp Area
Beta-actin 
Area Relative area Pgp Area
Beta-actin 
Area Relative area
48 - 1228.891 35648.59 0.03447236 24- 35376.6 26888.82 1.31566062
48 + 10615.62 41198.06 0.25767288 24+ 37810 31063.59 1.21718019
96- 24398.32 40486.84 0.60262355 24- 25944.8 31675.96 0.81907003
96+ 10291.17 41977.25 0.24516058 24+ 39321.7 37782.91 1.04072715
168- 18330.67 40008.49 0.45816956 24- 24355.8 45087.69 0.54018755
168+ 18370.11 36824.42 0.49885667 24+ 28026.8 35168.84 0.7969208
Experiment #7 Experiment #8
Experiment #1 Experiment #2
Experiment #3 Experiment #4
Experiment #5 Experiment #6
Resting  Lymphocytes Probed for P-glycoprotein
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Experiment #2
BXP-21 
Area
Beta-actin 
Area
Relative     
area
BXP-21 
Area
Beta-actin 
Area
Relative     
area
6- 13212.77 8324.974 1.58712388 6- 49307.1 14402.65 3.42347097
6+ 25035.81 9079.803 2.75730718 6+ 51997.4 16968.19 3.06440246
18- 10654.21 10482.56 1.01637463 18- 50586.1 22238.92 2.27466632
18+ 33844.31 15951 2.12176808 18+ 54839.9 20658.33 2.65461645
24- 7658.995 14794 0.51770972 24- 40239.4 15708.89 2.56157015
24+ 12568.77 14674.65 0.85649493 24+ 47001.8 14921.36 3.14996898
96- 39199.9 14388.22 2.72444445 48- 46647.5 20885.5 2.23348944
96+ 25070.46 10005.97 2.50554948 48+ 37965.2 20157.38 1.88343832
96- 35905.4 18562.97 1.9342493
96+ 52403.1 23576.45 2.22268958
168- 38543 17877.65 2.15593015
168+ 56003.6 19753.84 2.83507483
Experiment #3
BXP-21 
Area
Beta-actin 
Area
Relative 
area
6- 8036.773 16583.31 0.48463024
6+ 33963.39 19264.79 1.76297717
18- 36390.56 19160.21 1.89927808
18+ 41884.41 20855.4 2.00832451
24- 36702.39 23001.33 1.59566397
24+ 45282.83 21417.28 2.11431279
48- 48634.82 16112.5 3.01845244
48+ 52444.25 17657.04 2.97016158
96- 34442.61 19718.16 1.74674556
96+ 47511.87 23491.94 2.02247567
168- 40722.43 22086.74 1.84374999
168+ 54544.27 22857.87 2.3862366
Caco2 Cells Grown in Co-culture with Activated  Lymphocytes Probed for BCRP
Experiment #1
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Appendix D: Data
Pgp Area
Beta‐actin 
Area Relative area
BXP‐21 
Area
Beta‐actin 
Area Relative area
0nM 9751.815 34352.886 0.283871783 0nM 13869.14 25642.271 0.540870229
0.1nM 25328.51 43546.149 0.581647415 0.1nM 14831.64 27717.09 0.535108231
Pgp Area
Beta‐actin 
Area Relative area
BXP‐21 
Area
Beta‐actin 
Area Relative area
0nM 30974.32 48148.484 0.643308396 0nM 25902.53 54807.902 0.472605666
0.1nM 44945.6 57705.798 0.778874889 0.1nM 28339.79 58269.023 0.486361149
Pgp Area
Beta‐actin 
Area Relative area
BXP‐21 
Area
Beta‐actin 
Area Relative area
0nM 12211.94 37183.12 0.328426878 0nM 17219.74 47144.011 0.365258357
0.1nM 15060.42 34773.635 0.433098841 0.1nM 17695.2 37651.647 0.469971473
Prx‐SO3 
Area
2‐Cys‐
Prx 
Area
Relative 
area
0nM 755.335 25704 0.029386
0.1nM 2738.619 27749 0.098694
Experiment #2
Prx‐SO3 
Area
2‐Cys‐
Prx 
Area
Relative 
area
0nM 7494.894 42193 0.177633
0.1nM 11620.3 51691 0.224802
Prx‐SO3 
Area
2‐Cys‐
Prx 
Area
Relative 
area
Experiment #3
0nM 2919.589 35159 0.083039
0.1nM 1271.82 29048 0.043783
Experiment #3 Experiment #3
Resting Lymphocytes Treated with Tat for 24 
hours Probed for Peroxiredoxin Sulfate 
standardized to 2‐cys‐Peroxiredoxin
Experiment #1
Resting Lymphocytes Treated with Tat for 24 
hours Probed for P‐glycoprotein
Resting Lymphocytes Treated with Tat for 24 
hours Probed for BCRP
Experiment #1 Experiment #1
Experiment #2 Experiment #2
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